Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes
NCT03579160Phase 3Terminated
- Sponsor
- Brigham and Women's Hospital
- Start
- Jan 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of timolol maleate gel + placebo in wound, sponsored by Brigham and Women's Hospital. Started Jan 2019; status: terminated.
02
Drugs
timolol maleate gel + placebo
03
Conditions
wound
Beyond the preview
Go deeper on NCT03579160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03579160.